It was late 2015 when Lara Sullivan, M.D., first called me. At the time she was a VP at Pfizer and working closely with Freda Lewis-Hall, M.D., then the company’s chief medical officer. From their vantage point, they could see this tremendous pipeline flow of assets—along with what got funded — and what did not. “There were a number of programs that had great clinical data, but unfortunately, did not have a development path within Pfizer,” she elaborates.